Aaron Davenport and Jim Marden have joined SK Capital Partners as managing directors. They previously co-led the healthcare investment practice at Arsenal Capital Partners.
SK Capital Partners, a transformational private equity firm, today announced that it has expanded its investment team with the additions of Aaron Davenport and Jim Marden as Managing Directors. Both Mr. Davenport and Mr. Marden previously led the healthcare investing effort at Arsenal Capital Partners, where they worked closely with Barry Siadat and Jack Norris, two Managing Directors at SK Capital.
“Aaron, Jim and I collaborated on several successful investments while at Arsenal,” said Dr. Siadat, co-founder and Managing Director of SK Capital Partners. “I have the utmost respect for their investment judgment and deal execution capabilities and am excited to have them become an integral part of SK Capital going forward.”
Jamshid Keynejad, co-founder and Managing Director of SK Capital Partners said, “We are focused on expanding our sector expertise with exceptional talent and we could not be more pleased to have these two individuals join our firm. Their addition will provide a more focused investment effort in selected segments of healthcare, where they have a strong track record of generating exceptional returns for investors. The current environment represents an attractive time for Aaron and Jim to apply SK Capital’s transformational investment approach in healthcare.”
“Jim and I are very pleased to be working with Barry and Jack again to build on our successful track record of sourcing and improving niche leading companies and generating attractive returns for our investors,” said Mr. Davenport. Mr. Marden added, “We look forward to leveraging the deep and diverse SK Capital team in continuing to make successful investments in healthcare.”
Prior to joining SK Capital, Mr. Davenport was a Principal at Arsenal Capital Partners, where he co-led Arsenal’s healthcare investing efforts and served on the firm’s Operating and Investment committees. Mr. Davenport was with Arsenal from 2001 to 2009. Prior to joining Arsenal, Mr. Davenport was a healthcare industry strategy consultant with Braun Consulting and was previously Director of Business Strategy and Development for CB Richard Ellis/Whittier Partners. Mr. Davenport received a B.A. magna cum laude from Amherst College and an MBA from the Tuck School of Business at Dartmouth. He currently serves on the Board of Directors of Bend Research, Inc.
Prior to joining SK Capital, Mr. Marden was a Managing Director at Arsenal Capital Partners from 2001 to 2008, where he served on the firm’s Operating and Investment Committees and led their healthcare investing efforts. Prior to Arsenal, Mr. Marden was the Executive Vice President of Corporate Development of Medical Logistics, Inc., a transportation and logistics company focused on healthcare distribution. He was previously Vice President Acquisitions for Medco Containment Services, Inc., and Synetic, Inc. Mr. Marden received a B.S. in Finance from The Wharton School at the University of Pennsylvania and serves on the Board of Continuum Health Partners, a group of hospitals located in the New York City area.
About SK Capital
SK Capital Partners is a transformational private equity firm focusing on acquiring assets in which its partners have deep industry knowledge through previous experience and investments, and deploying substantive operational strategies to unlock value and deliver superior returns. These industries include niche segments of the specialty chemicals, materials and healthcare sectors. SK Capital Partners currently has two portfolio companies, Aristech Acrylics, a leading manufacturer of acrylic sheeting marketed under the brand name Acrystone®, and Avonite® solid surfaces, and Ascend Performance Materials, a world leader in proprietary technologies that are central to the production of nylon, plastics and synthetic fibers found in thousands of commercial and industrial products, including carpet, tires and apparel, as well as agricultural products, animal feed and personal care products. The combined revenues of SK Capital’s two portfolio companies exceed $2 billion.
For more information, please visit www.skcapitalpartners.com.